Clinical meaning
The neurochemistry of alcohol withdrawal involves dual neurotransmitter derangement. Chronic ethanol potentiates GABA-A receptor chloride conductance while inhibiting NMDA receptor calcium influx. Compensatory neuroadaptation reduces GABA-A receptor expression (particularly alpha-1 subunit) and upregulates NMDA receptor density (NR2B subunit) and voltage-gated calcium channels. Abrupt cessation unmasks massive excitatory drive with glutamate-mediated excitotoxicity causing neuronal death and seizures. The kindling hypothesis explains progressive worsening: each withdrawal episode sensitizes neurons to subsequent withdrawal through long-term potentiation-like mechanisms. The clinician must prescribe evidence-based pharmacological protocols, manage complex medical comorbidities, order and interpret diagnostic studies, and coordinate long-term alcohol use disorder treatment including medication-assisted treatment (MAT).
Diagnosis & workup
Diagnostics & workup: - Order comprehensive metabolic panel: assess hepatic function (AST:ALT ratio >2:1 suggests alcoholic liver disease), renal function, electrolytes - Order magnesium, phosphorus, and ionized calcium levels - Obtain blood alcohol level and urine drug screen on admission - Order CBC: evaluate for macrocytic anemia (elevated MCV), thrombocytopenia, leukocytosis - Order coagulation studies (PT/INR) to assess hepatic synthetic function - Order lipase to rule out concurrent pancreatitis - Obtain ECG to evaluate for QTc prolongation and arrhythmias - Consider CT head if altered mental status out of proportion to withdrawal or focal neurological findings